Pfizer Inc. PFE

The Motley Fool 14 nov

The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.

The Motley Fool 14 nov

The article compares Novo Nordisk and Pfizer as investment choices for 2027. Novo Nordisk dominates the high-growth obesity and diabetes treatment markets with blockbuster drugs like Wegovy and Ozempic, but faces pricing pressures and competition from rivals like Eli Lilly. Pfizer offers a diversified portfolio, stronger cash position ($14.3B vs $6.8B), and cheaper valuation, making it the better turnaround bet despite slower growth. Both companies face headwinds from pricing pressures and competitive threats.

The Motley Fool 14 nov

Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.

The Motley Fool 14 nov

Pfizer and AbbVie offer different appeals for income investors. Pfizer boasts a high 5.9% dividend yield with a manageable 89% free cash flow payout ratio, though it faces a patent cliff. AbbVie, a Dividend King with 53 consecutive years of dividend increases, offers lower yield (2.35%) but stronger growth prospects and has successfully navigated its own patent cliff with strong new products like Skyrizi and Rinvoq.

Zacks Investment Research 13 nov

Zacks analysts published research on 16 major stocks on November 13, 2026. Visa benefits from strong brand and digital growth but faces profitability pressures. ExxonMobil gains from low-cost production and expansion opportunities but faces commodity volatility risks. Pfizer underperforms peers due to patent expirations and subdued growth, though pipeline investments offer longer-term potential. Additional coverage includes U.S. Bancorp, Blackstone, Edwards Lifesciences, and others with mixed outlooks.